Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer
Publication

Publications

Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer

Title
Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer
Type
Article in International Scientific Journal
Year
2009
Authors
Juergen Bauer
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Julie Weng
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Electron Kebebew
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Vitor Trovisco
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Boris C Bastian
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 18 No. 6
Pages: 548-552
ISSN: 0906-6705
Publisher: Wiley-Blackwell
Scientific classification
FOS: Medical and Health sciences > Clinical medicine
Other information
Authenticus ID: P-003-JGB
Abstract (EN): Recently, germline variants of the melanocortin-1 receptor (MC1R) have been shown to be associated with an increased risk for BRAF mutant but not BRAF wild-type cutaneous melanoma. Similar to melanoma, BRAF mutations are also commonly found in papillary thyroid carcinomas. Furthermore, patients with melanoma have an increased risk for thyroid carcinoma and vice versa. To determine whether MC1R variation also represents a risk factor for BRAF mutant thyroid carcinomas, we sequenced BRAF and MC1R in two separate case-control cohorts. We demonstrate that MC1R is expressed in normal and neoplastic thyroid epithelial cells, albeit at lower levels than in melanocytes. In the first cohort of 66 follicular and 62 papillary thyroid carcinomas (PTC), and 128 matched controls from the San Francisco Bay Area we found no association between the number of MC1R variant alleles and thyroid cancer. Patients with BRAF-mutated tumors had a higher frequency of MC1R variant alleles than their matched controls (P = 0.039). However, contrary to the findings in melanoma, the odds ratio for having a BRAF mutant cancer decreased from 3.9 for carriers of one MC1R allele to 1.5 for carriers of two or more alleles. As the frequency of MC1R alleles varies highly among different ethnic populations, we analysed a second, ethnically more homogeneous cohort from Spain and Portugal, and found no association with PTC nor with BRAF-mutated PTC. Our data indicate that the strong association between BRAF mutations and MC1R variants previously found in melanoma does not extend to thyroid cancer.
Language: English
Type (Professor's evaluation): Scientific
Contact: bastian@cc.ucsf.edu
No. of pages: 5
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

In vitro and in vivo comparative study of cosmetic ingredients Coffee silverskin and hyaluronic acid (2016)
Article in International Scientific Journal
Rodrigues, F; Matias, R; Ferreira, M; Maria Helena Amaral; Beatriz B P P Oliveira
Chemoprevention of photocarcinogenesis by lycopene (2014)
Article in International Scientific Journal
Ascenso, A; Ribeiro, H; Marques, HC; Oliveira, H; Santos, C; Simoes, S
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-13 at 11:57:08 | Privacy Policy | Personal Data Protection Policy | Whistleblowing